Progyny, Inc.

Name: Progyny, Inc. standardized financial statements, quarterly
Creator: Listed

PGNYNasdaqCIK 1551306HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$350.5m, Q2 FY2026

Operating income$40.0m, Q2 FY2026

Net income$28.1m, Q2 FY2026

Progyny, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	281	270	278	304	287	298	324	333	313	318	329	351
Cost of revenue	$m	218	213	216	236	227	235	248	254	241	242	245	261
Gross profit	$m	62.6	56.9	62.4	68.3	59.2	63.4	75.8	79.0	72.8	76.9	83.1	89.3
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	1.5	2.3	2.6	3.1	2.8	3.3
Operating income	$m	18.2	13.8	18.5	20.7	12.5	15.8	24.2	24.4	21.5	15.2	35.4	40.0
Income tax	$m	5.0	2.8	5.6	8.6	7.5	7.1	11.5	10.0	10.1	5.4	12.7	13.1
Net income	$m	15.9	13.5	16.9	16.5	10.4	10.5	15.1	17.1	13.9	12.5	24.2	28.1
Diluted EPS	$ per share	0.16	0.13	0.17	0.17	0.11	0.12	0.17	0.19	0.15	0.14	0.29	0.34
Basic EPS	$ per share	0.17	0.14	0.18	0.18	0.12	0.12	0.18	0.20	0.16	0.15	0.30	0.36

Balance sheet

Cash and equivalents$152.6m, Q2 FY2026

Shareholders' equity$453.3m, Q2 FY2026

Progyny, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	158	97.3	115	95.0	91.5	162	109	133	134	112	132	153
Current assets	$m	611	640	682	582	546	473	568	594	622	552	502	513
Total assets	$m	727	757	794	699	660	607	730	761	795	742	698	716
Current liabilities	$m	193	186	206	225	208	169	237	220	210	202	236	240
Total liabilities	$m	211	203	223	242	225	185	263	246	235	226	259	263
Short-term borrowings	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	515	553	572	456	435	422	467	515	560	516	439	453

Cash flow

Operating cash flow$50.4m, Q2 FY2026

Capital expenditure$6.2m, Q2 FY2026

Share repurchases$30.0m, Q2 FY2026

Progyny, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	54.2	37.7	25.7	56.7	44.5	52.2	49.8	55.5	50.7	54.2	45.9	50.4
Capital expenditure	$m	1.0	0.7	0.9	0.9	1.8	1.9	2.8	5.3	4.7	5.6	6.3	6.2
Share repurchases	$m	0.0	0.0	23.8	160	61.5	55.1	0.0	0.0	0.0	81.7	119	30.0

Diluted shares (weighted)82.14m, Q2 FY2026

Progyny, Inc., shares, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	101	101	101	97.8	93.8	88.9	89.3	89.6	90.2	89.5	84.8	82.1

Shares outstanding: 76.73m at Jul 31, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.